FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308135962> ?p ?o ?g. }

• W4308135962 endingPage "A36" @default.
• W4308135962 startingPage "A35" @default.
• W4308135962 abstract "Abstract Background Prader-Willi syndrome (PWS), a rare genetic neurobehavioral-metabolic condition, is characterized by hyperphagia, accumulation of excess fat, hypotonia, and behavioral/psychological complications. There are no currently approved medications to treat hyperphagia in patients with PWS; DCCR is under development as a treatment for PWS. Objectives and methods The objective was to evaluate long-term safety of DCCR in individuals with PWS. 125 participants with genetically-confirmed PWS ≥4 years old with hyperphagia were treated with oral daily DCCR in multi-center studies conducted at 29 sites in the US and the UK: a 13-week, Phase 3, double-blind, placebo-controlled study (DESTINY PWS) and its long-term, open-label extension study (to 52 weeks and beyond). Enrolled participants had hyperphagia assessed by the Hyperphagia Questionnaire for Clinical Trials (HQ-CT). The target DCCR dose was ≥3.3 mg/kg (optimal dose 4.2 - 5.8 mg/kg). 103 patients received DCCR for 52 weeks and 54 patients received DCCR for at least 78 weeks. Results Overall, DCCR was well tolerated with the majority of adverse events (AEs), (77.6%) having grade 1 or 2 severity. Treatment-emergent adverse events (TEAEs) occurred in 98.4% of participants. Drug related TEAEs occurred in 80.0% of participants. Twenty participants experienced serious adverse events (SAEs), for which only two participants were considered drug related (one patient with peripheral/pulmonary edema and another with fluid retention). There were no Suspected Unexpected Serious Adverse Reactions (SUSARs) or SAEs leading to death. The most common TEAEs were hypertrichosis (61.6%), peripheral edema (34.4%), and hyperglycemia (22.4%). TEAEs infrequently resulted in discontinuation of study drug (7.2% of participants). These results are consistent with the observed safety profile of DCCR from prior studies. Consistent with the expected AE of hyperglycemia, fasting glucose rose through Week 26 (mean change from baseline ± SD mmol/L = 0.35±0.81) and returned nearly to baseline by 15 months of treatment (0.11±0.61). HbA1c followed a similar pattern, increasing at 26 weeks (mean change from baseline ± SD % = 0.19±0.50) and returning nearly to baseline by 15 months (0.03±0.38). In participants experiencing hyperglycemia, the AE resolved with continued treatment in about half of cases. Four participants experienced recurrent hyperglycemia. About 90% of cases of peripheral edema resolved while treatment continued, requiring infrequent dose adjustment (7%) or the need for diuretic treatment (3%). Most cases of hypertrichosis (&gt;80%) were mild and only in one instance led to discontinuation. About 35% of cases of hypertrichosis were resolved/resolving at Week 52. Conclusions DCCR was well tolerated beyond 52 weeks of administration. The most common treatment-emergent adverse events were expected based on prior studies of DCCR. These included hypertrichosis, peripheral edema and hyperglycemia, which were typically mild and resolved without treatment in most cases. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m., Sunday, June 12, 2022 12:54 p.m. - 1:59 p.m." @default.
• W4308135962 created "2022-11-08" @default.
• W4308135962 creator A5000179221 @default.
• W4308135962 creator A5008657734 @default.
• W4308135962 creator A5017155476 @default.
• W4308135962 creator A5018720903 @default.
• W4308135962 creator A5020402251 @default.
• W4308135962 creator A5025126436 @default.
• W4308135962 creator A5038455975 @default.
• W4308135962 creator A5039716945 @default.
• W4308135962 creator A5039874120 @default.
• W4308135962 creator A5040872267 @default.
• W4308135962 creator A5043861019 @default.
• W4308135962 creator A5045905377 @default.
• W4308135962 creator A5047195042 @default.
• W4308135962 creator A5047694010 @default.
• W4308135962 creator A5047835640 @default.
• W4308135962 creator A5050987497 @default.
• W4308135962 creator A5055733234 @default.
• W4308135962 creator A5064713420 @default.
• W4308135962 creator A5068075323 @default.
• W4308135962 creator A5074788450 @default.
• W4308135962 creator A5086083668 @default.
• W4308135962 creator A5090556361 @default.
• W4308135962 date "2022-11-01" @default.
• W4308135962 modified "2023-09-26" @default.
• W4308135962 title "RF24 | PSUN94 Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome" @default.
• W4308135962 doi "https://doi.org/10.1210/jendso/bvac150.074" @default.
• W4308135962 hasPublicationYear "2022" @default.
• W4308135962 type Work @default.
• W4308135962 citedByCount "0" @default.
• W4308135962 crossrefType "journal-article" @default.
• W4308135962 hasAuthorship W4308135962A5000179221 @default.
• W4308135962 hasAuthorship W4308135962A5008657734 @default.
• W4308135962 hasAuthorship W4308135962A5017155476 @default.
• W4308135962 hasAuthorship W4308135962A5018720903 @default.
• W4308135962 hasAuthorship W4308135962A5020402251 @default.
• W4308135962 hasAuthorship W4308135962A5025126436 @default.
• W4308135962 hasAuthorship W4308135962A5038455975 @default.
• W4308135962 hasAuthorship W4308135962A5039716945 @default.
• W4308135962 hasAuthorship W4308135962A5039874120 @default.
• W4308135962 hasAuthorship W4308135962A5040872267 @default.
• W4308135962 hasAuthorship W4308135962A5043861019 @default.
• W4308135962 hasAuthorship W4308135962A5045905377 @default.
• W4308135962 hasAuthorship W4308135962A5047195042 @default.
• W4308135962 hasAuthorship W4308135962A5047694010 @default.
• W4308135962 hasAuthorship W4308135962A5047835640 @default.
• W4308135962 hasAuthorship W4308135962A5050987497 @default.
• W4308135962 hasAuthorship W4308135962A5055733234 @default.
• W4308135962 hasAuthorship W4308135962A5064713420 @default.
• W4308135962 hasAuthorship W4308135962A5068075323 @default.
• W4308135962 hasAuthorship W4308135962A5074788450 @default.
• W4308135962 hasAuthorship W4308135962A5086083668 @default.
• W4308135962 hasAuthorship W4308135962A5090556361 @default.
• W4308135962 hasBestOaLocation W43081359621 @default.
• W4308135962 hasConcept C126322002 @default.
• W4308135962 hasConcept C142724271 @default.
• W4308135962 hasConcept C187212893 @default.
• W4308135962 hasConcept C197934379 @default.
• W4308135962 hasConcept C204787440 @default.
• W4308135962 hasConcept C27081682 @default.
• W4308135962 hasConcept C2777482430 @default.
• W4308135962 hasConcept C71924100 @default.
• W4308135962 hasConceptScore W4308135962C126322002 @default.
• W4308135962 hasConceptScore W4308135962C142724271 @default.
• W4308135962 hasConceptScore W4308135962C187212893 @default.
• W4308135962 hasConceptScore W4308135962C197934379 @default.
• W4308135962 hasConceptScore W4308135962C204787440 @default.
• W4308135962 hasConceptScore W4308135962C27081682 @default.
• W4308135962 hasConceptScore W4308135962C2777482430 @default.
• W4308135962 hasConceptScore W4308135962C71924100 @default.
• W4308135962 hasIssue "Supplement_1" @default.
• W4308135962 hasLocation W43081359621 @default.
• W4308135962 hasLocation W43081359622 @default.
• W4308135962 hasOpenAccess W4308135962 @default.
• W4308135962 hasPrimaryLocation W43081359621 @default.
• W4308135962 hasRelatedWork W1977915442 @default.
• W4308135962 hasRelatedWork W2035049801 @default.
• W4308135962 hasRelatedWork W2085830368 @default.
• W4308135962 hasRelatedWork W2109282245 @default.
• W4308135962 hasRelatedWork W2163740414 @default.
• W4308135962 hasRelatedWork W2374781999 @default.
• W4308135962 hasRelatedWork W2976934717 @default.
• W4308135962 hasRelatedWork W2987544514 @default.
• W4308135962 hasRelatedWork W4233016836 @default.
• W4308135962 hasRelatedWork W59643826 @default.
• W4308135962 hasVolume "6" @default.
• W4308135962 isParatext "false" @default.
• W4308135962 isRetracted "false" @default.
• W4308135962 workType "article" @default.